<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; FACT</title>
	<atom:link href="http://www.stockbloghub.com/tag/fact/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABT) Abbott a Step Closer to in Aquisition Facet Biotech</title>
		<link>http://www.stockbloghub.com/2010/04/09/abt-abbott-a-step-closer-to-in-aquisition-facet-biotech/33341</link>
		<comments>http://www.stockbloghub.com/2010/04/09/abt-abbott-a-step-closer-to-in-aquisition-facet-biotech/33341#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:21:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33341</guid>
		<description><![CDATA[Abbott (ABT) recently announced the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) for its cash tender offer for Facet Biotech Corporation’s (FACT) outstanding shares. Abbott had announced its plans to acquire Facet earlier in March 2010. The company is acquiring Facet for $27 per share. The total purchase price is approximately $722 million Incorporatedluding Facet’s projected cash and marketable securities of approximately $272 million. This acquisition should help enhance Abbott’s early and mid-stage immunology and oncology pipeline. Facet’s lead pipeline candidate, daclizumab, which is being developed in collaboration with Biogen Idec (BIIB), is being studied for the treatment of multiple sclerosis. Besides daclizumab, Facet has several compounds in its oncology pipeline that are being developed for different types of cancer Incorporatedluding multiple myeloma ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/abt-abbott-a-step-closer-to-in-aquisition-facet-biotech/33341/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Completes Starlims Buyout</title>
		<link>http://www.stockbloghub.com/2010/03/25/abt-abbott-labs-completes-starlims-buyout/31621</link>
		<comments>http://www.stockbloghub.com/2010/03/25/abt-abbott-labs-completes-starlims-buyout/31621#comments</comments>
		<pubDate>Thu, 25 Mar 2010 21:52:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31621</guid>
		<description><![CDATA[Abbott Labs (ABT) recently completed the acquisition of Starlims Technologies Ltd. for $123 million. Starlims is a leading provider of laboratory information management systems. It improves the reliability of laboratory sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities. The software is used to manage laboratory testing. We believe this acquisition will help Abbott strengthen its position in the global diagnostic testing market. The company should be able to build its position in laboratory informatics, which is an emerging and fast growing market that focuses on managing the data generated by laboratories. Abbott has been in acquisition mode over the past few quarters in a bid to strengthen its pipeline. Earlier this month, the company announced its intention to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/abt-abbott-labs-completes-starlims-buyout/31621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TRBN) Trubion Pharmaceuticals&#8217; Loss is Wider Than Expected</title>
		<link>http://www.stockbloghub.com/2010/03/23/trbn-trubion-pharmaceuticals-loss-is-wider-than-expected/31466</link>
		<comments>http://www.stockbloghub.com/2010/03/23/trbn-trubion-pharmaceuticals-loss-is-wider-than-expected/31466#comments</comments>
		<pubDate>Tue, 23 Mar 2010 17:54:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31466</guid>
		<description><![CDATA[Trubion Pharmaceuticals, Inc.’s (TRBN) fourth quarter fiscal 2009 net loss per share came in at 29 cents, wider than the Zacks Consensus Estimate by 10 cents. The year-ago loss was 36 cents. The year-over-year decline in loss for the reported quarter was attributable to higher revenues. Quarterly Results Revenue for the reported quarter came in at $5.2 million as against $4.3 million in the year-ago quarter, up 20.9%. Total operating expenses for the reported quarter decreased marginally to $10.4 million from $10.7 million in the year-ago quarter. The decrease was primarily attributable to lower outside manufacturing and laboratory expense. Research and development expenses for the reported quarter fell approximately 18.1% to $6.81 million. General and administrative costs for the reported quarter climbed approximately 52.1% year-over-year to $3.56 million. Yearly Results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/23/trbn-trubion-pharmaceuticals-loss-is-wider-than-expected/31466/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Laboratories on an Acquisition Spree</title>
		<link>http://www.stockbloghub.com/2010/03/10/abt-abbott-laboratories-on-an-acquisition-spree/30248</link>
		<comments>http://www.stockbloghub.com/2010/03/10/abt-abbott-laboratories-on-an-acquisition-spree/30248#comments</comments>
		<pubDate>Wed, 10 Mar 2010 20:01:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30248</guid>
		<description><![CDATA[Abbott (ABT) continues to be in an acquisition mode, recently announcing its intention to acquire Facet Biotech Corporation (FACT) for $27 per share. The total purchase price is approximately $722 million Incorporatedluding Facet’s projected cash and marketable securities of approximately $272 million. Last year, Facet rejected an offer from Biogen Idec Inc. (BIIB) on the ground that it was inadequate and not in the best interests of Facet’s stockholders. Abbott’s offer price of $27 is well above Biogen’s last offer of $17.50 and represents a 67% premium to Facet’s closing price on March 9, 2010. Facet shares were up 67.2% in after market trading. The acquisition of Facet should help enhance Abbott’s early and mid-stage immunology and oncology pipeline. Facet’s daclizumab, which is being developed in collaboration with Biogen is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/abt-abbott-laboratories-on-an-acquisition-spree/30248/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FACT) Facet Biotech Rejects Biogen Idec Again</title>
		<link>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636</link>
		<comments>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:27:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22636</guid>
		<description><![CDATA[Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech&#8217;s stockholders. Earlier this month, Biogen had come back with a revised offer of $17.50 per share (up from the previous offer of $14.50) and said that this is its “best and final&#8221; offer. The offer represents a 21% premium over the previous offer and a premium of approximately 98% over the closing price of Facet’s common stock on September 3, 2009, the day before Biogen announced its proposal to acquire all the outstanding shares of Facet. The offer is scheduled to expire at 12:00 midnight, New York City time, on Dec 16, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/fact-facet-biotech-rejects-biogen-idec-again/22636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Reports Higher Earnings</title>
		<link>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245</link>
		<comments>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245#comments</comments>
		<pubDate>Tue, 20 Oct 2009 22:38:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18245</guid>
		<description><![CDATA[Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth driver. Tysabri sales came in at $207 million, up 21% from the prior period. The company estimates that as of the end of September 2009, about 46,200 patients were on commercial and clinical Tysabri therapy worldwide. This represents an increase from the 43,300 patients reported by the company in the second quarter of 2009. Tysabri is an important growth driver and we expect the product, which is partnered with Elan (ELN), to cross $1 billion in worldwide sales in 2009. Meanwhile, Biogen’s lead multiple sclerosis (MS) product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation</title>
		<link>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157</link>
		<comments>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:06:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18157</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech stock have been tendered. Earlier this month, Facet’s board of directors unanimously recommended that its stockholders should reject Biogen’s tender offer under which the company is seeking to acquire for $14.50 per share in cash. The board determined that the offer is inadequate and not in the best interests of the stockholders. As a reminder, Biogen launched a hostile bid in September to acquire Facet by taking its offer directly to Facet’s shareholders. The deal is valued at approximately $356 million. Biogen ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/biib-biogen-extends-hostile-bid-for-facet-biotech-corporation/18157/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer</title>
		<link>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383</link>
		<comments>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383#comments</comments>
		<pubDate>Mon, 12 Oct 2009 17:02:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17383</guid>
		<description><![CDATA[In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet Biotech common stock for $14.50 per share in cash. The board has determined that the offer is inadequate and not in the best interests of the company’s stockholders. As a reminder, Biogen launched a hostile bid in September to acquire Facet for $14.50 per share by taking its offer directly to Facet’s shareholders. The deal is valued at approximately $356 million. Biogen had initially approached Facet with an offer of $15 per share on Aug 17, 2009. However, Facet did not accept the offer as the company doubted its benefit for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/12/fact-facet-investors-urged-to-deny-biogen-idec-tender-offer/17383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech</title>
		<link>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986</link>
		<comments>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:57:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15986</guid>
		<description><![CDATA[After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash balance is less than Biogen’s offer price. The deal is valued at approximately $356 million. The tender offer will expire at 12:00 midnight, ET, on Oct. 19, 2009. As a reminder, Biogen had initially approached Facet with an offer of $15 per share on Aug. 17, 2009. However, Facet did not accept the offer as the company believed that it was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

